Clinical Trial Detail

NCT ID NCT02511184
Title Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST